130 related articles for article (PubMed ID: 27219287)
1. Countering immunotoxin immunogenicity.
Flavell DJ
Br J Cancer; 2016 May; 114(11):1177-9. PubMed ID: 27219287
[No Abstract] [Full Text] [Related]
2. Monoclonal antibodies in adult acute lymphoblastic leukemia.
Kantarjian H
Hematology; 2012 Apr; 17 Suppl 1():S52-4. PubMed ID: 22507779
[TBL] [Abstract][Full Text] [Related]
3. In the spotlight: a novel CD37 antibody-drug conjugate.
Palomba ML; Younes A
Blood; 2013 Nov; 122(20):3397-8. PubMed ID: 24235129
[TBL] [Abstract][Full Text] [Related]
4. Immunotoxin: A new tool for cancer therapy.
Allahyari H; Heidari S; Ghamgosha M; Saffarian P; Amani J
Tumour Biol; 2017 Feb; 39(2):1010428317692226. PubMed ID: 28218037
[TBL] [Abstract][Full Text] [Related]
5. Reducing the immune response to immunotoxin.
Frankel AE
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):13-5. PubMed ID: 14734445
[No Abstract] [Full Text] [Related]
6. Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma.
Heinrich DA; Weinkauf M; Hutter G; Zimmermann Y; Jurinovic V; Hiddemann W; Dreyling M
Br J Haematol; 2015 Feb; 168(4):606-10. PubMed ID: 25292485
[No Abstract] [Full Text] [Related]
7. Monoclonal antibodies in the treatment of immune thrombocytopenic purpura (ITP).
Gómez-Almaguer D
Hematology; 2012 Apr; 17 Suppl 1():S25-7. PubMed ID: 22507772
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targets and recent advances in protein immunotoxins.
Madhumathi J ; Verma RS
Curr Opin Microbiol; 2012 Jun; 15(3):300-9. PubMed ID: 22647353
[TBL] [Abstract][Full Text] [Related]
9. Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin.
Zovickian J; Johnson VG; Youle RJ
J Neurosurg; 1987 Jun; 66(6):850-61. PubMed ID: 3033171
[TBL] [Abstract][Full Text] [Related]
10. Recent developments in immunotoxin therapy.
Ghetie MA; Vitetta ES
Curr Opin Immunol; 1994 Oct; 6(5):707-14. PubMed ID: 7826525
[TBL] [Abstract][Full Text] [Related]
11. Immunotoxin therapy of malignancy.
Grossbard ML; Nadler LM
Important Adv Oncol; 1992; ():111-35. PubMed ID: 1582669
[No Abstract] [Full Text] [Related]
12. [Monoclonal antibodies: development and clinical prospects].
Borchmann P; Riethmüller G; Engert A
Internist (Berl); 2001 Jun; 42(6):803-4, 807-14. PubMed ID: 11449627
[No Abstract] [Full Text] [Related]
13. Monoclonal antibodies. Targeted treatment.
Mayo Clin Health Lett; 2003 Mar; 21(3):1-3. PubMed ID: 12703461
[No Abstract] [Full Text] [Related]
14. Designing immunotoxins for cancer therapy.
Pennell CA; Erickson HA
Immunol Res; 2002; 25(2):177-91. PubMed ID: 11999171
[TBL] [Abstract][Full Text] [Related]
15. Recombinant antibody fragments and immunotoxin fusions for cancer therapy.
Brinkmann U
In Vivo; 2000; 14(1):21-7. PubMed ID: 10757057
[TBL] [Abstract][Full Text] [Related]
16. Toxic antibodies blitz tumours.
Ledford H
Nature; 2011 Aug; 476(7361):380-1. PubMed ID: 21866131
[No Abstract] [Full Text] [Related]
17. [Vasculitis: update 2014].
Fleck M; Aries PM; Iking-Konert C
Dtsch Med Wochenschr; 2014 Jun; 139(23):1234-6. PubMed ID: 24866957
[No Abstract] [Full Text] [Related]
18. Improving the efficacy of antibody-based cancer therapies.
Carter P
Nat Rev Cancer; 2001 Nov; 1(2):118-29. PubMed ID: 11905803
[TBL] [Abstract][Full Text] [Related]
19. Antibody internalization after cell surface antigen binding is critical for immunotoxin development.
Kuo SR; Alfano RW; Frankel AE; Liu JS
Bioconjug Chem; 2009 Oct; 20(10):1975-82. PubMed ID: 19785403
[TBL] [Abstract][Full Text] [Related]
20. A monoclonal immunotoxin against laryngeal carcinoma cells.
Zenner HP
Otolaryngol Pol; 1990; 44(3):214-5. PubMed ID: 2255554
[No Abstract] [Full Text] [Related]
[Next] [New Search]
